vTv Therapeutics Inc. announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective November 2, 2023 . Most recently, he served as Chief Medical Officer of Faeth Therapeutics Inc., a clinical stage developer of metabolic oncology therapies. Prior to Faeth, Dr. Strack was Senior Vice President in Clinical Development and Medical Affairs at Molecular Templates Inc., a clinical stage biopharmaceutical company developing novel therapeutics for oncology.

He also served as Consultant in Medical Affairs at Omeros Corporation, a clinical stage biopharmaceutical company focused on small-molecule and protein therapeutics for immunologic disorders. Before Omeros, Dr. Strack served in senior clinical and research and development roles at Progenics Pharmaceuticals, Asubio Pharmaceuticals Inc., a subsidiary of Daiichi-Sankyo, and Pfizer. Previously, Dr. Strack began his industry career at Eli Lilly & Company, holding multiple positions including a Senior Regulatory Scientist in U.S. Regulatory Affairs, Oncology, Clinical Research Physician in Lilly Research Laboratories, and Associate Medical Director (Lilly Canada) in Diabetes/Endocrinology, Cardiovascular, and Oncology.

Dr. Strack earned his M.D. and his Doctorate from Johannes Gutenberg University.